← Browse by Condition
Medical Condition

immune related adverse event

Total Trials
4
Recruiting Now
4
Trial Phases
Phase 2

ClinicalMetric tracks all active clinical trials for immune related adverse event sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — immune related adverse event Clinical Trials

How many clinical trials are currently recruiting for immune related adverse event?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for immune related adverse event, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for immune related adverse event?
immune related adverse event research spans Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a immune related adverse event clinical trial?
Eligibility criteria for immune related adverse event trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
1
Top Sponsors
Tianjin Medical University Cancer Institute and Hospital 1 trial
Universitair Ziekenhuis Brussel 1 trial
AHS Cancer Control Alberta 1 trial
Xijing Hospital 1 trial

Recruiting Clinical Trials

NCT06702566
Recruiting

The Effect of Serum Ferritin in irAE

Enrollment
1,500 pts
Location
China
Sponsor
Tianjin Medical University Can...
View Trial →
NCT05832606
Recruiting

Food Intervention to Reduce Immunotherapy ToXicity

Enrollment
60 pts
Location
Belgium
Sponsor
Universitair Ziekenhuis Brusse...
View Trial →
NCT06860542 Phase 2
Recruiting

Inhaled Budesonide for REcurrence Prevention and Adjuvant THerapy in Checkpoint Inhibitor Pneumonitis

Enrollment
94 pts
Location
Canada
Sponsor
AHS Cancer Control Alberta
View Trial →
NCT06613165
Recruiting

Exploring the Treatment Duration of PD-1 Neoadjuvant Therapy in Stage II-III dMMR Rectal Cancer

Enrollment
100 pts
Location
China
Sponsor
Xijing Hospital
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology